DIMT1 overexpression correlates with progression and prognosis in gastric carcinoma

Publication date: Available online 7 June 2017
Source:Human Pathology
Author(s): Guangyi Liu, Xudong Peng, Yongqian Cai, Anqi Cheng, Lang Zha, Ziwei Wang
We investigated the expression of dimethyladenosine transferase 1 homolog (DIMT1) in human gastric carcinoma (GC) tissues, pericarcinoma histologically normal tissues (PCHNTs), and normal gastric tissues and explored its clinical significance. Immunohistochemistry staining was used to detect the expression of DIMT1, and the findings were compared with clinicopathologic features of patients with GC. The result also was ascertained by Western blotting. The Kaplan–Meier method and log-rank test were employed to compare the overall survival rate and time in the DIMT1 low-level and high-level expression groups. Immunohistochemical staining indicated that the expression of DIMT1 in GC tissues (65 of 75; 86.7%) was significantly more common (P<.001) than that in PCHNTs (14 of 75; 18.7%) and normal gastric tissues (2 of 12; 16.7%). High expression of DIMT1 correlated closely with differentiation (P=.023), invasion (P=.042), lymph node metastasis (P=.008), distant metastasis (P=.006), and TNM stage (P=.013). Western blotting showed that DIMT1 expression correlated positively with TNM stage and implied that more advanced TNM stage was accompanied by higher expression of DIMT1 (P<.001). Kaplan–Meier survival analysis showed that high DIMT1 expression correlated significantly (P<.001) with a poor prognosis. Our data suggest that DIMT1 is a useful molecular biomarker to predict tumor progression and prognosis in patients with GC.



http://ift.tt/2r9soRN